Xenon Pharmaceuticals Inc. Q3 2025 Earnings Recap

XENE Q3 2025 November 4, 2025

Get alerts when XENE reports next quarter

Xenon Pharmaceuticals continues to demonstrate strong momentum, with successful patient randomization in its Phase III X-TOLE2 study for azetukalner, while also expanding its therapeutic focus beyond epilepsy.

Earnings Per Share Beat

$-1.15 vs $-1.16 est.

+0.9% surprise

Market Reaction

1-Day -4.94%

5-Day -6.98%

30-Day +8.75%

See XENE alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed successful randomization of 380 patients for the Phase III X-TOLE2 trial, exceeding initial targets.
Top line data readout expected in early 2026, maintaining high confidence in positive outcomes based on historical study results.
Evaluating broader therapeutic applications for azetukalner in major depressive disorder and bipolar depression, supported by robust preclinical and clinical evidence.
Advancing early-stage pipeline with promising candidates in ion channel programs, signaling growth potential beyond current epilepsy focus.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit XENE on AllInvestView.